Fig. 4From: Development and evaluation of mucoadhesive bigel containing tenofovir and maraviroc for HIV prophylaxisa HeLa cell cytotoxicity of API from maraviroc tenofovir bigel formulations; results are expressed as % cell viability compared to HeLa cells without any treatment (n = 3 ± SD). b HIV infectivity dose-response curves for maraviroc from maraviroc tenofovir bigel formulations incubated with HIV-1 indicator TZM-bl cells at different concentrations (n = 5 ± SD)Back to article page